Matulonis, U., Lorusso, D., Oaknin, A., Pignata, S., Dean, A., Denys, H., et al. (2023). Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. OBSTETRICAL & GYNECOLOGICAL SURVEY, 78(6), 343-344 [10.1097/01.ogx.0000943180.30391.de].

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Colombo N.;
2023

Editoriale, introduzione, contributo a forum/dibattito
antibody conjugate; bevacizumab; cytotoxic agent; folate receptor 1; mirvetuximab soravtansine; platinum derivative
English
2023
78
6
343
344
none
Matulonis, U., Lorusso, D., Oaknin, A., Pignata, S., Dean, A., Denys, H., et al. (2023). Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. OBSTETRICAL & GYNECOLOGICAL SURVEY, 78(6), 343-344 [10.1097/01.ogx.0000943180.30391.de].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/563673
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact